On March 16, 2018 Medigene AG (FSE: MDG1, Prime Standard, TecDAX) reported its participation at the following upcoming conferences (Press release, , 16 16, 2018, View Source [SID1234524860]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Annual Needham Healthcare Conference
Date: 27 – 28 March 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 28 March.
analytica
Date: 10 – 13 April 2018
Location: Munich, Germany
Dr. Thomas Taapken, CFO of Medigene, takes part in a panel discussion on personalized medicine during the conference on 13 April, from 10.35am – 12pm.
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting
Date: 14 – 18 April 2018
Location: Chicago, USA
Medigene and its clinical partners will present a poster on manufacturing data from the ongoing DC vaccine trial on April 18, 2018, 8:00 AM – 12:00 PM in Section 29. To view the abstract of the poster entitled "Generation of clinical grade autologous TLR7/8-polarized fast dendritic cell vaccines for active immunotherapy of patients with AML" please visit: View Source
German Biotechnology Days
Date: 18 – 19 April 2018
Location: Berlin, Germany
Dr. Thomas Taapken, CFO of Medigene, takes part in a panel discussion on "USA – Key market for international business" during the conference on 19 April, from 8am – 9am.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.